Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance

Kate Bridges(Yale University), Gabriela A. Pizzurro(Yale University), Alev Baysoy(Yale University), Janani Baskaran(Yale University), Ziyan Xu(Salk Institute for Biological Studies), Varsha Mathew(Salk Institute for Biological Studies), Victoria Tripple(Salk Institute for Biological Studies), Michael LaPorte(Salk Institute for Biological Studies), Koonam Park(Yale University), William Damsky(Yale University), Harriet M. Kluger(Yale Cancer Center), Rong Fan(Yale Cancer Center), Susan M. Kaech(Salk Institute for Biological Studies), Marcus Bosenberg(Yale Cancer Center), Kathryn Miller‐Jensen(Yale University)
bioRxiv (Cold Spring Harbor Laboratory)
October 31, 2024
Cited by 0Open Access
Full Text

Abstract

Effective cancer immunotherapies restore anti-tumor immunity by rewiring cell-cell communication. Treatment-induced changes in communication can be inferred from single-cell RNA-sequencing (scRNA-seq) data, but current methods do not effectively manage heterogeneity within cell types. Here we developed a computational approach to efficiently analyze scRNA-seq-derived, single-cell-resolved cell-cell interactomes, which we applied to determine how agonistic CD40 (CD40ag) alters immune cell crosstalk alone, across tumor models, and in combination with immune checkpoint blockade (ICB). Our analyses suggested that CD40ag improves responses to ICB by targeting both immuno-stimulatory and immunosuppressive macrophage subsets communicating with T cells, and we experimentally validated a spatial basis for these subsets with immunofluorescence and spatial transcriptomics. Moreover, treatment with CD40ag and ICB established coordinated myeloid-T cell interaction hubs that are critical for reestablishing antitumor immunity. Our work advances the biological significance of hypotheses generated from scRNA-seq-derived cell-cell interactomes and supports the clinical translation of myeloid-targeted therapies for ICB-resistant tumors.


Related Papers

No related papers found

Powered by citation graph analysis